Marek Jutel

Allergen-specific immunotherapy with recombinant grass pollen allergens.

Histamine receptors in immune regulation and allergen-specific immunotherapy.

Clinical results from vaccination with recombinant grass pollen allergens.

T-cell subset regulation in atopy.

Immunological mechanisms of allergen-specific immunotherapy.

Recombinant allergens: the present and the future.

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

Research needs in allergy: an EAACI position paper, in collaboration with EFA.

Human T regulatory cells: on the way to cognition.

Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development.

Allergen-Specific Immunotherapy in Asthma.

Novel immunotherapy vaccine development.

T-cell regulation during viral and nonviral asthma exacerbations.

International consensus on allergy immunotherapy.

International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics.

Allergen immunotherapy for allergic asthma: protocol for a systematic review.

Allergen Immunotherapy: Past, Present, and Future.

Sublingual immunotherapy (SLIT)--indications, mechanism, and efficacy: Position paper prepared by the Section of Immunotherapy, Polish Society of Allergy.

Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.

Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease.

Histamine-secreting microbes are increased in the gut of adult asthma patients.

Validation of the Global Allergy and Asthma European Network (GALEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber.

Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis.

A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease.

Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews.

EAACI guidelines on allergen immunotherapy: Prevention of allergy.

Erratum to: Allergen immunotherapy for allergic asthma: protocol for a systematic review.

Peak nasal inspiratory flow as outcome for provocation studies in allergen exposure chambers: a GALEN study.

Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document.

2019 ARIA Care pathways for allergen immunotherapy.

Severe asthma: Entering an era of new concepts and emerging therapies: Highlights of the 4th international severe asthma forum, Madrid, 2018.

Prioritizing research challenges and funding for allergy and asthma and the need for translational research-The European Strategic Forum on Allergic Diseases.

EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.

Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019.

Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases.

Food and drug allergy, and anaphylaxis in EAACI journals (2018).

Highlights and recent developments in airway diseases in EAACI journals (2018).

Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence.

State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI).

Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients.

Perspectives in allergen immunotherapy: 2019 and beyond.

Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma.

ARIA guideline 2019: treatment of allergic rhinitis in the German health system.

Biologicals in atopic disease in pregnancy: An EAACI position paper.

Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement.

In-vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan-An EAACI position paper.

Placebo effects in allergen immunotherapy-An EAACI Task Force Position Paper.

Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement.

EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network.

Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma.

Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement.

ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice.

COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.

A compendium answering 150 questions on COVID-19 and SARS-CoV-2.

Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI).

ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).

Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model.

Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI).

Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.

Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Spices to Control COVID-19 Symptoms: Yes, but Not Only….

ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper.

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines.

Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19.

Allergen immunotherapy: The growing role of observational and randomized trial "Real-World Evidence".

COVID-19 pandemic and allergen immunotherapy-an EAACI survey.

Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation.

The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective.

Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA LEN consensus.

Real-life impact of COVID-19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section.

Management of anaphylaxis due to COVID-19 vaccines in the elderly.

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report.

ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.

COVID-19 vaccines-The way forward.

Spermidine and spermine exert protective effects within the lung.

EAACI Biologicals Guidelines-Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old.

Advances and highlights in asthma in 2021.

Climate change: A call to action for the United Nations.

Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.

The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID-19.

Development and validation of combined symptom-medication scores for allergic rhinitis.

Climate change and global health: A call to more research and more action.

COVID-19  vaccination in patients receiving allergen immunotherapy (AIT) or biologicals-EAACI recommendations.

AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper.

Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air real-world data.

Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model.

Serum Allergen-Specific IgE among Pediatric Patients with Primary Immunodeficiency.

Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference.

Diagnostic Challenges in Patients with Inborn Errors of Immunity with Different Manifestations of Immune Dysregulation.

The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis.

Validated allergen exposure chamber is plausible tool for the assessment of house dust mite-triggered allergic rhinitis.

Real-world evidence for the long-term effect of allergen immunotherapy: Current status on database-derived European studies.

Interferon Gamma Targeted Therapy: Is It Justified in Primary Sjögren's Syndrome?

Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long-term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis.

Histamine: A Mediator of Intestinal Disorders-A Review.

Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

Immunotherapy: State-of-the-art review of therapies and theratypes.

Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities.

Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

EAACI guidelines on environmental science in allergic diseases and asthma - Leveraging artificial intelligence and machine learning to develop a causality model in exposomics.